{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:07:21Z","timestamp":1773986841371,"version":"3.50.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,7,1]]},"DOI":"10.1001\/jamaoncol.2021.1463","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T18:17:50Z","timestamp":1622744270000},"page":"1005","source":"Crossref","is-referenced-by-count":32,"title":["Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Felix Y.","family":"Feng","sequence":"first","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibu","family":"Thomas","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gormley","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret K.","family":"Yu","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah S.","family":"Ricci","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Rooney","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, High Wycombe, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Brookman-May","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[{"name":"Spanish National Cancer Research Centre, Madrid, Spain"},{"name":"Institituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Guy\u2019s, King\u2019s and St. Thomas\u2019 Hospitals, Great Maze Pond, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[{"name":"West German Cancer Center, Department of Urology, University of Duisburg-Essen, Essen, Germany"},{"name":"Department of Urology, University Hospital Heidelberg, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Decipher Biosciences Inc, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[{"name":"Decipher Biosciences Inc, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"13","key":"coi210018r1","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi210018r2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy.","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"coi210018r3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy.","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"coi210018r4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer.","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"coi210018r5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdz397","article-title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.","volume":"30","author":"Small","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"coi210018r6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"coi210018r7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer.","volume":"36","author":"Spratt","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi210018r8","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy.","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"key":"coi210018r9","doi-asserted-by":"publisher","first-page":"10798","DOI":"10.1038\/ncomms10798","article-title":"Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat Commun"},{"issue":"20","key":"coi210018r11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"coi210018r12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ygeno.2012.08.003","article-title":"A single-sample microarray normalization method to facilitate personalized-medicine workflows.","volume":"100","author":"Piccolo","year":"2012","journal-title":"Genomics"},{"issue":"22","key":"coi210018r14","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1158\/1078-0432.CCR-19-1587","article-title":"Transcriptomic heterogeneity of androgen receptor activity defines a de novo low ar-active subclass in treatment na\u00efve primary prostate cancer.","volume":"25","author":"Spratt","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9747","key":"coi210018r15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"coi210018r16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer.","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"coi210018r17","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide.","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"coi210018r18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"coi210018r19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"coi210018r20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"coi210018r21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer.","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"coi210018r22","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"coi210018r23","first-page":"6063","article-title":"Molecular and cellular mechanisms of castration resistant prostate cancer.","volume":"15","author":"Huang","year":"2018","journal-title":"Oncol Lett"},{"issue":"8","key":"coi210018r24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/1758834017719215","article-title":"Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.","volume":"9","author":"Terada","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"coi210018r25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2020.38.6_suppl.276","article-title":"Transcriptome profiling of NRG oncology\/RTOG 9601: validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial","volume":"38","author":"Feng","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi210018r26","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1200\/JCO.2020.38.15_suppl.5535","article-title":"Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN","volume":"38","author":"Feng","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi210018r27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1200\/JCO.2020.38.6_suppl.162","article-title":"Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): a correlative study of E3805 CHAARTED","volume":"38","author":"Hamid","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi210018r28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccr.2012.01.005","article-title":"Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation.","volume":"21","author":"Choi","year":"2012","journal-title":"Cancer Cell"},{"issue":"22","key":"coi210018r29","doi-asserted-by":"publisher","first-page":"12315","DOI":"10.1073\/pnas.1922207117","article-title":"Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.","volume":"117","author":"Alumkal","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"coi210018r10","unstructured":"A study of apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer (SPARTAN): NCT01946204. Updated April 5, 2021. Accessed September 21, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01946204"},{"key":"coi210018r13","unstructured":"Decipher Genomics Resource Information Database (GRID). NCT02609269. Updated March 6, 2019. Accessed September 23, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02609269"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2780477\/jamaoncology_feng_2021_oi_210018_1626360255.64836.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T15:01:50Z","timestamp":1626361310000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2780477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.1463","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}